Biomed Instrum Technol. 2021 Mar 1;55(s3):58-66. doi: 10.2345/0899-8205-55.s3.58.
When investing in X-ray irradiation facilities around the world, an opportunity exists for defining a regulatory framework for assessing the transition from current gamma irradiation processes. Historically, regulatory strategies for changing the radiation source for routine processing has consisted of repeating the majority, if not all, of the validation activities performed as part of an initial validation and associated submission. Although not a new concept, performing a risk assessment has the potential to be leveraged more fully by increasing the rigor of determining what is changing when product moves from a gamma to an X-ray irradiator, then determining how these differences may affect product characteristics. During these steps, differences can be identified and quantified between radiation sources and potential impacts, if any, to product quality can be elucidated. Based on these risk assessments, the level of action required, or not required, in terms of empirical product testing can be examined and a determination can be made regarding whether a substantial change has occurred.
在投资世界各地的 X 射线辐照设施时,可以为评估从当前伽马辐照工艺过渡制定一个监管框架。从历史上看,改变常规处理辐射源的监管策略包括重复进行初始验证和相关提交所做的大部分(如果不是全部)验证活动。尽管这不是一个新概念,但通过增加确定产品从伽马射线辐照器转移到 X 射线辐照器时发生变化的严格程度,然后确定这些差异如何影响产品特性,可以更充分地利用风险评估。在这些步骤中,可以识别和量化辐射源之间的差异,并阐明任何对产品质量的潜在影响。基于这些风险评估,可以检查在经验产品测试方面需要采取或不需要采取的行动水平,并确定是否发生了实质性变化。